Oncotarget: Addiction To Runx1 Is Partially Attenuated By Loss Of P53

Oncotarget: Addiction to Runx1 is partially attenuated by loss of p53

The role of P53 in the early detection of sarcoma

Genetic Modifiers of p53: Opportunities for Breast Cancer Therapies | Oncotarget

The Role of p53 in Cancer

Artificial Intelligence: Revolutionizing Precision Oncology | Oncotarget

Prion like aggregation on mutant p53 in cancer

Dr. Rule on Patients With p53-Mutated MCL

CDR3s and Renalase-1 Correlate with Increased Melanoma Survival | Oncotarget

Novel strategies to target P53-mutant hematological malignancies

VJHemOnc – Video Journal of Hematology & HemOnc

Is there a use for anti-PDL-1 antibodies in recurrent head and neck cancer?

Everolimus Inhibits Angiogenesis, Lymphangiogenesis in TP53 Mutant HNSCC | Oncotarget

Beating the Odds 10 Year Lung Cancer Survivor Shares Her Optimism

Patient Empowerment Network

Unresectable Melanoma—Targeted or Immunotherapy?

One More Step Toward Treatment of PARP Inhibitor-resistant Ovarian Cancers | Oncotarget

ON203: the anti-oxMIF antibody targeting solid tumors

Different mutant RUNX1 Oncoproteins Program

Oncotarget: Llgl1 prevents metaplastic survival

Oncotarget: Breast cancer cells to ONC201 from anti-proliferative to apoptotic

Oncotarget: AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis